BPO 0.00% 0.3¢ bioprospect limited

Prostate Cancer Nutraceutical

  1. Oak
    1,815 Posts.
    BioProspect’s role with this product is purely in relation to the research and development of the product. InterHealth Biotechnologies (formerly Lane Laboratories) are responsible for the registration and marketing of this product. Currently, IHB has submitted data to the relevant regulatory authority for its final ratification and they have been awaiting clearance on this product to allow IHB to launch and market the product in the USA. The submission has been with the regulatory body for over six months and BioProspect and IHB are in their hands in regards to their processing of the submission. Until we have formal notification from IHB and the regulators, it is inappropriate for us to release information on the launch date for this particular product.

    Hopefully this information is helpful.

    Best Regards

    Selwyn Snell


watchlist Created with Sketch. Add BPO (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.